Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,503 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07017686Recruiting
Reboot Study: Nerve stimulation for rheumatoid arthritis
This study tests a device that sends mild electrical pulses to the vagus nerve in the abdomen to treat rheumatoid arthritis. It is for people whose arthritis has not improved after trying multiple medications.
Fitzroy, VictoriaAges 18–75 - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07039669RecruitingPhase 3
Study of 611 for moderate to severe COPD in adults
This trial tests a new medicine called 611 for people with moderate to severe COPD. It aims to see if adding 611 to your current treatments can help prevent flare-ups and improve symptoms.
Beijing, Beijing MunicipalityAges 40–85 - NCT07042126RecruitingPhase 3
Testing 611 for Teen Eczema (moderate to severe)
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
Beijing, Beijing MunicipalityAges 12–17 - NCT07056673Recruiting
Cold plasma for moderate to severe acne
This study tests whether a treatment called 'cold atmospheric plasma' (similar to a gentle, cool gas) can improve moderate-to-severe acne. It might offer a new, drug-free option for people with many pimples or cysts.
Luoyang, HenanAges 18–40 - NCT07056660Recruiting
Cold plasma for athlete's foot
This trial tests a new device that uses cold plasma (a gas with charged particles) to treat moderate-to-severe athlete's foot. It may be an option if standard creams haven't worked or you want to try a non-medication approach.
Luoyang, HenanAges 18–70 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07083193RecruitingPhase 1/Phase 2
Study of AC-101 tablets for moderate to severe ulcerative colitis
This trial tests a new tablet called AC-101 for people with active moderate to severe ulcerative colitis. It aims to see if the drug can reduce symptoms like diarrhea and bleeding and help the gut heal.
Guangzhou, GuangdongAges 18–75 - NCT07087353Recruiting
Remote monitoring for moderate to severe depression
This study tests whether checking in with a mental health team remotely (using your phone) can help people with moderate to severe depression feel better. It’s designed for people who are already getting treatment and want extra support from home.
BesançonAges 18 years+ - NCT07109765Recruiting
Secukinumab for moderate to severe hidradenitis suppurativa
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07152366RecruitingPhase 4
Hormone and tetuzumab for active thyroid eye disease
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07152340RecruitingPhase 4
Sequential hormone and IBI311 therapy for active TAO
This trial tests a two-step treatment for active, moderate-to-severe thyroid eye disease (TAO). You will first receive hormone therapy, followed by a drug called IBI311. The goal is to see if this sequence works better for people who have not had steroid treatment before.
Changhua, Shanghai MunicipalityAges 18–80 - NCT07161960Recruiting
Early vs. delayed gallbladder removal after drainage
This trial compares removing the gallbladder early (within a few days) versus waiting several weeks after a drainage tube is placed. It aims to find the best timing for surgery in people with moderate to severe gallbladder inflammation.
Chiang MaiAges 20 years+ - NCT07165002RecruitingPhase 1
Study of LY3537031 in people with and without liver problems
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
KistarcsaAges 18–85 - NCT07177911RecruitingPhase 1
Study of CC312 for moderate to severe lupus
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Chengdu, SichuanAges 18–65 - NCT07184944RecruitingPhase 3
Study of Duvakitug for moderate to severe Crohn's disease
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
Colorado Springs, ColoradoAges 16–80 - NCT07189806Recruiting
Asthma study tracking symptoms over 5 years
This study follows adults with mild, moderate, or severe asthma to better understand the condition. You'll attend regular check-ups at the clinic to monitor your lung function and symptoms over five years.
LondonAges 18 years+ - NCT07228221RecruitingPhase 4
Study of iStent and iDose for moderate to severe glaucoma
This trial studies a new treatment (a tiny device called iStent Infinite and a medication implant) for people with moderate to severe open-angle glaucoma who have not responded well to drops or laser. The goal is to see if this treatment can lower eye pressure and help avoid traditional surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07233291RecruitingPhase 2
Roflumilast pills for moderate to severe psoriasis in adults
This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07235904RecruitingPhase 4
Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
KielAges 18–75 - NCT07241117RecruitingPhase 4
CHEST: Helping clinics use SMART for asthma
This study tests a program to help community health clinics use a special asthma treatment approach called SMART. The goal is to see if it improves asthma care and reduces flare-ups.
St Louis, MissouriAges 12 years+
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,503 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.